NASDAQ:LEXX Lexaria Bioscience (LEXX) Stock Price, News & Analysis $2.64 +0.02 (+0.76%) (As of 07/3/2024 ET) Add Compare Share Share Today's Range$2.55▼$2.6850-Day Range$2.19▼$4.0052-Week Range$0.71▼$6.85Volume25,675 shsAverage Volume347,721 shsMarket Capitalization$34.03 millionP/E RatioN/ADividend YieldN/APrice Target$12.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Lexaria Bioscience alerts: Email Address Lexaria Bioscience MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside354.5% Upside$12.00 Price TargetShort InterestHealthy1.22% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.46) to ($0.41) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.58 out of 5 starsMedical Sector419th out of 911 stocksPharmaceutical Preparations Industry192nd out of 430 stocks 3.5 Analyst's Opinion Consensus RatingLexaria Bioscience has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageLexaria Bioscience has received no research coverage in the past 90 days.Read more about Lexaria Bioscience's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.22% of the float of Lexaria Bioscience has been sold short.Short Interest Ratio / Days to CoverLexaria Bioscience has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lexaria Bioscience has recently decreased by 25.69%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldLexaria Bioscience does not currently pay a dividend.Dividend GrowthLexaria Bioscience does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LEXX. Previous Next 3.0 News and Social Media Coverage News SentimentLexaria Bioscience has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Lexaria Bioscience this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for LEXX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows5 people have added Lexaria Bioscience to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lexaria Bioscience insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.61% of the stock of Lexaria Bioscience is held by insiders.Percentage Held by InstitutionsOnly 13.06% of the stock of Lexaria Bioscience is held by institutions.Read more about Lexaria Bioscience's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Lexaria Bioscience are expected to grow in the coming year, from ($0.46) to ($0.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lexaria Bioscience is -3.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lexaria Bioscience is -3.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLexaria Bioscience has a P/B Ratio of 8.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Lexaria Bioscience's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you must get in now. Don’t delay.See all the details you need here. About Lexaria Bioscience Stock (NASDAQ:LEXX)Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.Read More LEXX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LEXX Stock News HeadlinesMay 23, 2024 | theglobeandmail.comLexaria Bioscience (NASDAQ: LEXX) Granted Two New US Patents in Hypertension, EpilepsyMay 21, 2024 | finance.yahoo.comLexaria Receives Two New Medical-Treatment Patents in Hypertension and EpilepsyJuly 3, 2024 | Paradigm Press (Ad)Elon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you must get in now. Don’t delay.May 20, 2024 | theglobeandmail.comLexaria (NASDAQ: LEXX) Announces Commencement of Dosing in GLP-1 Animal StudyMay 17, 2024 | theglobeandmail.comLexaria Bioscience (NASDAQ: LEXX) Looking to Tap into Various Growing MarketsMay 17, 2024 | finanznachrichten.deLexaria Bioscience Corp.: Dosing Begins in Lexaria's Comprehensive GLP-1 Animal StudyMay 10, 2024 | theglobeandmail.comLexaria (NASDAQ: LEXX) Set to Extend Runway to 2025 Following Warrant Exercise, IssuanceMay 9, 2024 | theglobeandmail.comLexaria Bioscience (NASDAQ: LEXX) Begins Dosing of Human Pilot Study No. 2, GLP-1-H24-2July 3, 2024 | Paradigm Press (Ad)Elon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you must get in now. Don’t delay.May 8, 2024 | theglobeandmail.comLexaria (NASDAQ: LEXX) Targeting Massive Type 2 Diabetes and Obesity Markets with DehydraTECH(TM)May 8, 2024 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria Begins Dosing of Its Second GLP-1 Human Pilot StudyMay 7, 2024 | theglobeandmail.comLexaria (NASDAQ: LEXX) Launches New Research Program to Evaluate DehydraTECH-GLP-1 DrugsApril 30, 2024 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise and IssuanceApril 17, 2024 | msn.comLexaria Bioscience, BioSig Technologies, BIMI Holdings among healthcare moversApril 16, 2024 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 StudyApril 5, 2024 | morningstar.comLexaria Bioscience Corp LEXXMarch 19, 2024 | theglobeandmail.comLexaria (NASDAQ: LEXX) Marks 2024 Milestone with FDA Clearance for Planned U.S. Phase 1b Hypertension TrialMarch 18, 2024 | proactiveinvestors.comLexaria Bioscience Revolutionizes Drug Delivery with DehydraTECH for GLP-1 drugMarch 15, 2024 | theglobeandmail.comLexaria Bioscience (NASDAQ: LEXX) Names Experienced Corporate Finance Exec as New CFOMarch 14, 2024 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria Appoints Nelson Cabatuan as Chief Financial OfficerMarch 7, 2024 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria Awards Contract For Next GLP-1 Human Pilot StudyMarch 5, 2024 | msn.comLexaria to test DehydraTECH GLP-1 product for weight loss, diabetesMarch 4, 2024 | finanznachrichten.deLexaria Bioscience Corp.: 7% Weight Loss in Animals Supports Lexaria's Next 8-week Animal StudyMarch 4, 2024 | finance.yahoo.com7% Weight Loss in Animals Supports Lexaria’s Next 8-week Animal StudyMarch 1, 2024 | msn.comLexaria slips despite FDA nod to test blood pressure drugFebruary 18, 2024 | finance.yahoo.comThis Lexaria Bioscience Insider Increased Their Holding By 23% Last YearFebruary 16, 2024 | finance.yahoo.comLexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesSee More Headlines Receive LEXX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lexaria Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/09/2024Today7/03/2024Next Earnings (Estimated)7/12/2024Fiscal Year End8/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:LEXX CUSIPN/A CIK1348362 Webwww.lexariabioscience.com Phone(250) 765-6424FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$12.00 Low Stock Price Target$12.00 Potential Upside/Downside+361.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,660,000.00 Net MarginsN/A Pretax Margin-1,417.36% Return on Equity-133.97% Return on Assets-118.89% Debt Debt-to-Equity RatioN/A Current Ratio66.29 Quick Ratio66.29 Sales & Book Value Annual Sales$230,000.00 Price / Sales145.71 Cash FlowN/A Price / Cash FlowN/A Book Value$0.33 per share Price / Book7.88Miscellaneous Outstanding Shares12,890,000Free Float11,905,000Market Cap$33.51 million OptionableNot Optionable Beta1.00 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Christopher A. Bunka (Age 62)Chairman & CEO Comp: $291.19kMr. John M. Docherty M.Sc. (Age 55)President & Director Comp: $290.46kMr. Nelson D. Cabatuan CPA (Age 45)Chief Financial Officer Kristin HamiltonDirector of OperationsVanessa CarleHead of LegalDr. Philip N. Ainslie Ph.D.Advisor & ConsultantMore ExecutivesKey CompetitorsAdlai NortyeNASDAQ:ANLProQR TherapeuticsNASDAQ:PRQRSyros PharmaceuticalsNASDAQ:SYRSAdageneNASDAQ:ADAGG1 TherapeuticsNASDAQ:GTHXView All CompetitorsInstitutional OwnershipInvenomic Capital Management LPSold 258,716 shares on 5/16/2024Ownership: 3.672%Welch Group LLCBought 24,000 shares on 4/9/2024Ownership: 0.194%View All Institutional Transactions LEXX Stock Analysis - Frequently Asked Questions Should I buy or sell Lexaria Bioscience stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lexaria Bioscience in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" LEXX shares. View LEXX analyst ratings or view top-rated stocks. What is Lexaria Bioscience's stock price target for 2024? 1 Wall Street analysts have issued 12-month price targets for Lexaria Bioscience's shares. Their LEXX share price targets range from $12.00 to $12.00. On average, they expect the company's share price to reach $12.00 in the next year. This suggests a possible upside of 354.5% from the stock's current price. View analysts price targets for LEXX or view top-rated stocks among Wall Street analysts. How have LEXX shares performed in 2024? Lexaria Bioscience's stock was trading at $1.25 at the beginning of 2024. Since then, LEXX stock has increased by 111.2% and is now trading at $2.64. View the best growth stocks for 2024 here. Are investors shorting Lexaria Bioscience? Lexaria Bioscience saw a drop in short interest during the month of June. As of June 15th, there was short interest totaling 153,000 shares, a drop of 25.7% from the May 31st total of 205,900 shares. Based on an average daily trading volume, of 240,500 shares, the short-interest ratio is currently 0.6 days. Currently, 1.2% of the shares of the stock are sold short. View Lexaria Bioscience's Short Interest. When is Lexaria Bioscience's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, July 12th 2024. View our LEXX earnings forecast. How were Lexaria Bioscience's earnings last quarter? Lexaria Bioscience Corp. (NASDAQ:LEXX) released its quarterly earnings results on Tuesday, April, 9th. The company reported ($0.06) earnings per share for the quarter. The company had revenue of $0.15 million for the quarter. How do I buy shares of Lexaria Bioscience? Shares of LEXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LEXX) was last updated on 7/3/2024 by MarketBeat.com Staff From Our PartnersOperation Replace Biden is a GoLast night’s debate proved me right: Joe Biden will be replaced. I’ve been making this warning for months… ...The Freeport Society | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine...InvestorPlace | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredThe End of Privacy for Americans… Get Out of Cash Now!Unlock the Secret to Outsmarting Inflation with "The Trump Loophole" That investment? Gold.Golden Crest | SponsoredSilver Expected for Extreme Price ActionOur newest Silver Investing Guide reveals how savvy investors are capitalizing on silver's continued rise – PL...Colonial Metals | SponsoredDid Joe Biden just reveal his replacement?The Democrats are scheming to remove Biden as their presidential nominee… And absolute chaos will ensue.Paradigm Press | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexaria Bioscience Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexaria Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.